Acupan
(Nefopam)Phase 3Small molecule
Nefopam is a pain reliever used to treat moderate pain after surgery or injuries. It works differently than common painkillers like acetaminophen or ibuprofen.[1] Acupan is currently being investigated across 10 indications[3], with its most advanced program in Phase 3.[1]
Acupan is one of 145 small molecule programs targeting Lung Cancer. It is currently in Phase 3.
10
Indications
22
Total Trials
3
Active Trials
144
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Acupan
YYonsei University
Phase 3
Chantix
PPrism Pharmaceuticals
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Paracetamol
GSKPreclinical
Zoladex
Luye Pharma Group Ltd.Preclinical
Metfomin
UUniversity of Texas Southwestern Medical Center
Preclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Recombinant Human Chorionic Gonadotropin
Merck & Co.Preclinical
Tetracycline Hydrochloride
EEuropean Organisation for Research and Treatment of Cancer - EORTC
Preclinical
Leronlimab
CCytoDyn, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Analgesic2 trials
Prevention2 trials
15 more indications
Total Hip Arthroplasty1 trial
Patient-Controlled Analgesia1 trial
Post Operative Pain1 trial
Critically Ill Patients1 trial
Adjuvant Continuous Infusion of Nefopam Versus Standard of Care in Mechanically Ventilated Critically Ill Patients: Randomized Double-blind Controlled Study
Completed·—·Phase 3·NCT05071352·60 enrolled
Acute Postoperative Pain1 trial
Intraoperative1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nefopam. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- YYonsei University